Drug Discovery

Geron announces telomerase licensing agreement

Published in Gene Therapy Weekly, April 29th, 2004

Geron Corp. (GERN) and Xcellsyz, Ltd., announced that Geron has granted to Xcellsyz a nonexclusive license to Geron's human telomerase reverse transcriptase (hTERT) technology for research applications and the development of research products.

Under the terms of the agreement, Xcellsyz will use hTERT to create immortalized cell lines for in-vitro use in drug discovery and screening. The license is limited to cell lines that also include a recombinant conditionally inducible oncogene, using Xcellsyz's own proprietary technology. In connection with the license, Geron will receive a license fee payment in cash and equity in Xcellsyz as well as royalties on future product...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-04-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry